特拉斯图苏马布的潜力 德鲁克斯泰康作为一种组织不可知药物
1Medical Science, Dx-Rx Institute, Fredensborg, Denmark.
Oncology
|August 31, 2023
概括
特拉斯图祖马布德鲁克斯泰坎作为一种组织不可知药物具有前景,有可能治疗各种HER2阳性先进固体瘤. 进一步的研究正在进行中,以确认其广泛的疗效,并解决未满足的医疗需求.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 现代抗癌药物越来越多地针对特定的分子变化.
- 组织不可知药物针对这些变化,而不论癌症的起源.
- 美国食品和药物管理局根据癌症类型的分子点来定义组织无关药物.
研究的目的:
- 为了评估trastuzumab deruxtecan (T-DXd) 的组织不可知潜力.
- 评估T-DXd在HER2阳性先进固体瘤中的疗效.
- 为那些选择有限的患者确定潜在的新疗法选择.
主要方法:
- 审查已公布的第一阶段数据.
- 对DESTINY-PanTumor02第二阶段试验的中间结果的分析.
- 探索正在进行的临床研究在各种固体瘤与HER2改变.
主要成果:
- 特拉斯图祖马布德鲁克斯泰干 (T-DXd) 已批准用于特定的HER2-阳性和HER2-低癌症.
- 临时数据表明,T-DXd可能有利于患有各种 HER2 阳性高级固体瘤的患者.
- 初步发现表明T-DXd.的潜在瘤活性.
结论:
- 在HER2阳性先进固体瘤中,T-DXd显示出有前途的泛瘤活性.
- 目前正在进行的试验至关重要,以确认T-DXd的组织不可知性分类.
- T-DXd可能会解决少数治疗选择的患者的重大未满足的医疗需求.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


